Background: Anticancer immune response has been reported to contribute the success of chemotherapy. The aim of this study was to evaluate the significance of the measurement of tumor-infiltrating lymphocytes (TILs) in primary tumor as a prognostic marker of the chemotherapeutic outcomes in patients with stage IV colorectal cancer.